247 publications

Enter search criteria

Fill in keyword(s) to narrow your search.

Fill in a starting date and a closing date for the period your query is about: DD-MM-YYYY

You can select a specific type of a publication you are looking for, such as press releases or speeches

Tenofovir alafenamide (Vemlidy®) for the treatment of chronic hepatitis B infection

Zorginstituut Nederland carried out an assessment of the medicine tenofovir alafenamide (Vemlidy®). Based on the criteria of the ...

Report | 26-04-2017

Migalastat (Galafold®) for the treatment of Fabry's disease

Zorginstituut Nederland carried out an assessment of whether, based on the criteria of the Medicines Reimbursement System (GVS), ...

Report | 25-04-2017

Elosulfase alfa (Vimizim®) for the treatment of Morquio A syndrome

Zorginstituut Nederland carried out a reassessment of the medicinal product elosulfase alfa (Vimizim®).

Report | 24-04-2017

Ibrutinib (Imbruvica®) for the treatment of chronic lymphatic leukaemia

Zorginstituut Nederland carried out an assessment of the medicinal product ibrutinib (Imbruvica®), for the first-line treatment ...

Report | 24-04-2017

Cysteamine with delayed release (Procysbi®)

Zorginstituut Nederland carried out an assessment of the medicine cysteamine with delayed release (Procysbi®) whereby they ...

Report | 23-03-2017

A paradigm shift in perception, learning and action - summary of the second advice of the Committee Innovation Health Care Professions & Education

Summary of the second report of The Committee Innovation Health Care Professions & Education.

Report | 23-03-2017

Daclizumab (Zinbryta®) for the treatment of relapsing (recidive) forms of multiple sclerosis (RMS)

Zorginstituut Nederland carried out a marginal assessment of the medicine daclizumab (Zinbryta ® ), whereby they came to the ...

Report | 15-12-2016

Palbociclib (Ibrance®) for the treatment of metastatic breast cancer

Zorginstituut Nederland carried out an assessment of the medicine palbociclib (Ibrance®), whereby they came to the following ...

Report | 15-12-2016

Netupitant - palonosetron (Akynzo®) for the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy

Zorginstituut Nederland has assessed the medicine netupitant/palonosetron (Akynzeo®), whereby they came to the following ...

Report | 31-10-2016

Zinnige Zorg room for improvement report - Appropriate use of pharmaceutical products for patients with castration-refractory prostate cancer (CRPC)

Within the framework of the Zinnige Zorg Programme, Zorginstituut Nederland systematically assesses the Dutch minimal and ...

Report | 29-07-2016